e-learning
resources
Madrid 2019
Tuesday, 01.10.2019
Pulmonary hypertension: novelties from the bench
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Implication of Enhancer of Zeste Homolog 2 in Pulmonary Arterial Hypertension
S. Bonnet (Québec, Canada), K. Habbout (Québec, Canada), J. Omura (Québec, Canada), R. Paulin (Québec, Canada), S. Provencher (Québec, Canada), O. Boucherat (Québec, Canada)
Source:
International Congress 2019 – Pulmonary hypertension: novelties from the bench
Session:
Pulmonary hypertension: novelties from the bench
Session type:
Poster Discussion
Number:
5053
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Bonnet (Québec, Canada), K. Habbout (Québec, Canada), J. Omura (Québec, Canada), R. Paulin (Québec, Canada), S. Provencher (Québec, Canada), O. Boucherat (Québec, Canada). Implication of Enhancer of Zeste Homolog 2 in Pulmonary Arterial Hypertension. 5053
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on Basic translational and clinical research – building a career in paediatric pulmonology- experiences from clinicians in lower middle income countries
ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions
Definition and history of sarcoidosis
Related content which might interest you:
Role of CHK1 in Pulmonary Arterial Hypertension
Source: International Congress 2018 – Pathobiology of pulmonary hypertension
Year: 2018
Right Ventricular Failure in an Animal Model of Severe Pulmonary Arterial Hypertension: eNOS Uncoupling and Protein Kinase G Signaling in the Transition from Adaptive to Maladaptive Remodeling
Source: Research Seminar 2005 - Pulmonary Circulation: Molecular Determinants of Pulmonary Vascular Remodelling
Year: 2005
Multi-Omics Analysis of the PDGF Response in Pulmonary Vascular Smooth Muscle Cells from Patients with Pulmonary Arterial Hypertension: Implication of the NMDAR
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
Pulmonary Arterial Hypertension Affects the Rat Gut Microbiome
Source: International Congress 2018 – Pathobiology of pulmonary hypertension
Year: 2018
Microvascular Endothelial Function in treated Pulmonary Arterial Hypertension
Source: International Congress 2017 – Imaging and lung disease PH
Year: 2017
Contribution of BMP9 to Pulmonary Arterial Hypertension
Source: International Congress 2017 – New perspectives from experimental models of pulmonary hypertension
Year: 2017
Role of class IIa histone deacetylases in the pathogenesis of pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014
Effects on Right Ventricular size and function by Riociguat in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension (The RIVER Study)
Source: International Congress 2018 – Pulmonary hypertension: therapy
Year: 2018
Late Breaking Abstract - Chronic Hypoxia Promotes Pulmonary Venous Smooth Muscle Cells Proliferation by Upregulating Calcium Sensing Receptor
Source: International Congress 2018 – Molecular mechanisms and treatment of pulmonary hypertension
Year: 2018
LSC - 2017 - Proteasomal Activator 200 (PA200) Regulates Cellular Proliferation: A Putative Role For IPF And Lung Cancer Pathogenesis
Source: International Congress 2017 – New insights into pathogenesis of lung disease
Year: 2017
Long Non-coding RNA H19 in Right Ventricular Failure associated with Pulmonary Arterial Hypertension
Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench
Year: 2019
Gene-Gene Interaction between EPAS1 and EGLN1 in Patients with High-Altitude Pulmonary Edema
Source: International Congress 2018 – Experimental research in pulmonary hypertension
Year: 2018
Effects of Long Term Exogenous Apelin Application in Experimental Pulmonary Hypertension Model Created with Monocrotaline
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
Liquid biopsy for Chronic Thromboembolic Pulmonary Hypertension: Circulating microRNA profile by Next Generation Sequencing
Source: International Congress 2017 – PAH and CTEPH
Year: 2017
A Minimal Clinically Important Difference for CAMPHOR in Idiopathic Pulmonary Arterial Hypertension
Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension
Year: 2020
Acetylsalicylic Acid Prevents Intermittent Hypoxia-Induced Vascular Remodeling in a Murine Model of Sleep Apnea
Source: International Congress 2018 – Pathophysiological aspects of sleep-disordered breathing: intermittent hypoxia
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept